A dire reaction: rash after amiodarone administration.

[1]  N. Moiemen,et al.  Toxic epidermal necrolysis: retrospective analysis of 21 consecutive cases managed at a tertiary centre , 2010, Clinical and experimental dermatology.

[2]  J. Roujeau,et al.  Open trial of ciclosporin treatment for Stevens–Johnson syndrome and toxic epidermal necrolysis , 2010, The British journal of dermatology.

[3]  R. Salisbury.  Toxic epidermal necrolysis (TEN) and Stevens–Johnson syndrome (SJS): Experience with high-dose intravenous immunoglobulins and topical conservative approach: A retrospective analysis , 2009 .

[4]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[5]  M. Mockenhaupt,et al.  Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. , 2008, Journal of the American Academy of Dermatology.

[6]  M. Stella,et al.  Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. , 2007, Burns : journal of the International Society for Burn Injuries.

[7]  M. Jonkman,et al.  Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis. , 2007, Acta dermato-venereologica.

[8]  T. Sluysmans,et al.  Acute epidermal necrolysis of Lyell syndrome , 1987, European Journal of Pediatrics.

[9]  Martine Bagot,et al.  Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. , 2004, The Journal of allergy and clinical immunology.

[10]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[11]  J. Roujeau,et al.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. , 2000, The Journal of investigative dermatology.

[12]  C. Brun-Buisson,et al.  Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis , 1998, The Lancet.

[13]  J. Tschopp,et al.  Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. , 1998, Science.

[14]  R. Schwartz.  Toxic epidermal necrolysis. , 1997, Cutis.

[15]  R. Stern,et al.  Severe adverse cutaneous reactions to drugs. , 1994, The New England journal of medicine.

[16]  R. Stern,et al.  Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. , 1993, Archives of dermatology.

[17]  P. Bencini,et al.  Toxic epidermal necrolysis and amiodarone treatment. , 1985, Archives of dermatology.